Cryoaugmentation-clinical pregnancy rates per oocyte retrieval procedure including all subsequent frozen embryo transfers

2008 ◽  
Vol 90 ◽  
pp. S426
Author(s):  
O. Pirrello ◽  
J. Craig ◽  
E. McVeigh ◽  
T. Child
Author(s):  
Robabe Hosseinisadat ◽  
Lida Saeed ◽  
Sareh Ashourzadeh ◽  
Sedigheh Safar Heidari ◽  
Victoria Habibzadeh

Background: Several mediators play an important role in implantation. One of these mediators is human chorionic gonadotropin (HCG). Objective: To evaluate the effects of HCG intrauterine injection on the day of oocyte retrieval on the result of assisted reproductive techniques (ART). Materials and Methods: In this randomized clinical trial study, 126 women who were referred to Afzalipour Infertility Center between December 2018 to December 2019 undergoing in vitro fertilization/intracytoplasmic sperm injection cycles were enrolled and assigned to two groups of: a case (n = 62) and a control group (n = 64). The protocols for both groups were the same; except that the case group was injected with the protocols for both groups were the same, except that the case group was injected with 1000 IU of HCG into uterine cavity following the oocyte puncture, while no medication was administered to the control group. The implantation rate, chemical pregnancy, clinical pregnancy, and abortion rates were compared between the two groups. Results: Positive chemical pregnancy was seen in 15 (27.3%) cases of the case group and 14 (25.5%) of the control group. No significant difference was seen in the chemical and clinical pregnancy rates between the groups. The abortion rate was higher in the control group but that was not significant. Conclusion: A 1000 IU of HCG intrauterine injection after oocyte retrieval does not improve implantation, chemical or clinical pregnancy rates in ART cycles. Further studies are needed to clearly understand the role of HCG intrauterine injection in the day of oocyte retrieval in ART outcomes. Key words: Oocyte retrieval, Chorionic gonadotropin, Pregnancy, Assisted reproductive techniques.


2016 ◽  
Vol 28 (2) ◽  
pp. 216
Author(s):  
A. Kotlyar ◽  
R. Flyckt ◽  
N. Desai

Anti-Mullerian hormone (AMH) levels are often used in an IVF population for assessment of ovarian reserve. However, it is not well understood whether AMH levels predict implantation and clinical pregnancy in older women undergoing IVF. In this study, we sought to compare IVF outcomes and morphokinetic parameters in patients 38 years and older with normal versus low AMH levels. Experimental design was a single-centre, retrospective cohort study. Time-lapse imaging data were evaluated for patients 38 years and older (n = 81). Patients were divided into those with AMH values less than 1.0 (n = 47) versus greater than or equal to 1.0 (n = 34). Morphokinetic data was then analysed from transferred blastocysts from these patients cultured in the Embryoscope until transfer (n = 100). The morphokinetic parameters examined were time to 2 cell (t2), 4 cell(t4), 5 cell (t5), time to synchronous divisions (s2, s3), duration of the second cell cycle (cc2), and third cell cycle (cc3). Implantation and clinical pregnancy were identified based upon the presence of a gestational sac. Fertilization, implantation, clinical pregnancy, and blastocyst formation rates were compared between normal and low AMH groups (Table 1). Mean morphokinetic parameters were compared between the 2 AMH groups using an unpaired t-test. Chi-squared tests were used for proportions. P < 0.05 was considered statistically significant. Results: Age of the patients ranged from 38–43, (41.3 ± 2.2 years). The results are summarised below. There were significant differences between implantation and clinical pregnancy rates for low and normal AMH levels. Morphokinetic parameters among the transferred embryos did not differ significantly between the 2 AMH groups (NS, data not shown). Conclusions: This initial data indicates that, in an IVF population 38 years and older, AMH levels greater than or equal to the cutoff of 1 ng mL–1 are associated not only with increased oocyte retrieval, but also with increased implantation rates and clinical pregnancy rates. These differences suggest that AMH may have a predictive role in determining the likelihood of clinical pregnancy in the 38 years and older patient population. Table 1.Oocyte harvest and IVF outcomes


2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
S Romero ◽  
R Pella ◽  
F Escudero ◽  
K Pérez ◽  
M García ◽  
...  

Abstract Study question Is elective frozen blastocyst transfer an advantageous strategy for all patients? Summary answer A freeze-all strategy improves the outcomes in patients with few available embryos. What is known already With the aim of defining the best moment to perform embryo transfer, in recent years, relevance has been given to the understanding of the implantation window, however oocyte and embryo quality are key factors that are not to be disregarded. It has been suggested that a freeze-all strategy and subsequent frozen embryo transfers improve pregnancy rates. However, it is unclear whether this strategy benefits all kind of patients (i.e. with or without surplus embryos, etc). In this study, we aim to provide an answer on which patients may benefit of a freeze-all policy and a subsequent frozen embryo transfer. Study design, size, duration This retrospective cohort study includes infertile patients aged 21 to 44 years old, without previous history of recurrent failure of ART (including recurrent miscarriages). Enrolments took place between January 2015 and November 2019 and cycles with oocyte donation and PGT were excluded. Embryo transfers were performed in: 1) a fresh cycle (ET) or 2) a deferred cycle with surplus frozen embryos (FET) or embryos that were frozen in a freeze-all policy (FET-FA). Participants/materials, setting, methods Patients with blastocysts transfer were included. PGT cycles were excluded. The number of cycles complying with the inclusion criteria were: 617 ICSI cycles. Fresh embryo transfers (ET) were performed in 396 cycles (43 with a subsequent Frozen embryo transfer, FET). Frozen embryo transfers following a freeze-all strategy (FET-FA) were performed in 221 cycles. Clinical pregnancy rates (CPR) and Cumulative clinical pregnancy rates (CCPR) were calculated and compared among those groups. Main results and the role of chance Mean age of patients was 36.1 ± 3.7 years old (mean ± SD). In average, 1.83 ± 0.41 (mean ± SD) embryos were transferred. Following the first transfer (either ET and FET-FA), CPR was 40.4% and 58.4% (ET and FET-FA, respectively). Following the subset analysis of 2 age groups (≤38 & &gt;38 years-old); in the ≤38-group, CPR was 45.2% and 58.9% (ET and FET-FA, respectively), while in &gt; 38-group, the rates were 30.8% and 54.8% (ET and FET-FA, respectively); p &lt; 0.05. CCPR were also significantly better in the FET-FA group: 51.3% vs 66.8% and 33.8% vs 58.1% in the ≤38-group and &gt;38-group, respectively. Additionally, CPR was analysed independently for patients with ≤2 usable embryos (1 attempt) or ≥ 3 usable embryos (surplus embryos after first attempt). When a single attempt was possible; in the ≤38-group, CPR was 36.1% and 56.9% (ET and FET-FA, respectively) while in the &gt;38-group, the rates were 24.7% and 63.6% (ET and FET-FA, respectively); p &lt; 0.05. When surplus embryos were available, no difference in CPR (or CCPR) between ET and FET-FA groups were observed. After first attempt CPR were 58.4% and 48.2% in the ≤38-group & &gt;38-group, respectively; while CCPR were 69.8% and 57.1% in the ≤38-group & &gt;38-group, respectively. Limitations, reasons for caution Although the authors consider that the patient population is of optimal size, a detailed analysis of the stimulation protocol and hormonal values (estradiol and progesterone) during treatment, and its potential relation to the outcomes, should follow. Wider implications of the findings: In our setting, the data suggests that freeze-all strategy (with subsequent frozen embryo transfer) over fresh transfer is advantageous for patients with few available embryos (1 or 2 embryos for a single attempt). This increases the chances to pregnancy in 30.3% in the ≤38-group and 77.9% in the &gt;38-group. Trial registration number Not applicable


2012 ◽  
Vol 98 (3) ◽  
pp. S274-S275
Author(s):  
D.A. Kelk ◽  
S.S. Richlin ◽  
A.C. Fusina ◽  
E.L. Paganetti ◽  
S.L. Vadehra ◽  
...  

2008 ◽  
Vol 90 ◽  
pp. S349 ◽  
Author(s):  
E.M. Kolibianakis ◽  
K. Loutradi ◽  
C.A. Venetis ◽  
E.G. Papanikolaou ◽  
T.B. Tarlatzi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document